Key result
Aspirin combined with a proton pump inhibitor is preferred over clopidogrel for minimizing the risk of recurrent gastrointestinal bleeding in patients requiring antiplatelet therapy.
Why the study?
Clinicians need guidance on balancing gastrointestinal bleeding risks against cardiovascular risks when choosing, stopping, or restarting antiplatelet agents like aspirin and clopidogrel.
What is the optimal management of aspirin and clopidogrel in patients with recent bleeding or at risk for gastrointestinal bleed?
What is the optimal management of aspirin and clopidogrel in patients with recent bleeding or at risk for gastrointestinal bleed?
This review provides clinical guidance on the decision-making process for managing aspirin and clopidogrel in patients with or at risk for gastrointestinal bleeding.
Balancing antiplatelet benefits against GI bleed risks requires individualized assessment; leaves open definitive recommendations from higher-level evidence.
Antiplatelet agents are used worldwide mainly for primary and secondary prevention of cardiovascular events on a long-term basis for mortality benefit. Gastrointestinal bleeding is a well-known adverse effect. Various factors are to be considered while choosing antiplatelet agents to prevent the risk of bleed and rebleed incidents. These range from deciding on the agent, timing of therapy, underlying indications, coadministration of proton pump inhibitor, etc. At the same time, one must weigh the risks of cardiovascular events secondary to the stoppage of antiplatelet therapy. With this review, we have tried to guide the clinician on decision-making regarding the care of patients on management of acute upper and lower gastrointestinal bleeding, stoppage, restarting of agents, and measures to prevent a recurrence. We have focused on aspirin and clopidogrel as they are among the most widely used antiplatelet agents.
No takes yet. Share an insight, caveat, or question.
Gosavi et al. (2023) conducted a review in Gastrointestinal bleeding risk with antiplatelet therapy. Antiplatelet therapy (Aspirin and Clopidogrel) was evaluated. Aspirin combined with a proton pump inhibitor is preferred over clopidogrel for minimizing the risk of recurrent gastrointestinal bleeding in patients requiring antiplatelet therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: